Increased vimentin mRNA expression in MCF-7 breast cancer cell line after repeated endoxifen-treatment

Paramita, Paramita; Louisa, Melva; Nafrialdi, Nafrialdi

doi:10.13181/mji.v25i4.1397

Cited by 2 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, treatment effectiveness is limited by high rates of de novo and acquired resistance during treatment [8]. E, an active metabolite of TMX, can also fail because of acquired resistance [6,7]. Hence, the aim of the present study was to determine the efficacy of CM administered for the prevention of decreased sensitivity of BC cells to E by coadministration with β-E2.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have argued that epithelial-mesenchymal transition, which is characterized by increased vimentin expression, might play a significant role in the development of E resistance [7]. In addition, Squirewell et al [14] argued that E may affect the ability of human Drug efflux transporters are involved in the decreased sensitivity of BC cells to TMX [9,10].…”

Section: Discussionmentioning

confidence: 99%

“…E exerts its anticancer effects by degrading ER alpha, which leads to the inhibition of estrogen-induced BC cell proliferation [4]. However, BC cell resistance to endocrine treatment, including E, is likely to develop overtime [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Modulation of Drug Efflux Transporter by Curcumin in McF7 Breast Cancer Cells After Repeated Exposure of Endoxifen and Estradiol

et al. 2018

Self Cite

View full text Add to dashboard Cite

Objective:The aim of the present study was to determine whether curcumin (CM) can prevent drug sensitivity of breast cancer (BC) cells when E and β-E2 are administered together and whether the underlying mechanism involves modulation of drug efflux transporters.Methods: MCF7 BC cells were treated with the vehicle only, E+β-E2, or E+β-E2+CM repeatedly for 8 weeks. Afterward, the cells were harvested, counted, and isolated for total RNA extraction. Total RNA was then processed into cDNA and further processed for the determination of mRNA expression patterns of drug efflux transporters (P-glycoprotein, BCRP, and MRP1). Results:Decreased sensitivity of BC cells was shown by the increased cell viability of MCF7 cells after 8 weeks. This condition was accompanied with increased mRNA expression of P-glycoprotein, BCRP, and MRP1 in cells treated with E+β-E2, as compared with the vehicle only. CM, administered in combination with E+β-E2, resulted in decreased cell viability versus E and β-E2 and also decreased in mRNA expression of P-glycoprotein, BCRP, and MRP1.Conclusion: CM partially reversed the sensitivity loss of BC cells to E in the presence of β-E2 by modulating drug efflux transporters.

show abstract

Section: Discussionmentioning

confidence: 99%